Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial
Authors' conclusion
These results suggest that tailored interventions such as tirzepatide dosage adjustments may help optimise the treatment management of Japanese patients with obesity disease.
Study context
- Population
- Japanese adults with obesity disease, excluding diabetes; subgroups by sex, age (<65, ≥65 years) and body mass index (BMI) (<35, ≥35 kg/m²)
- Participants
- 225 adults
- Comparison
- Once-weekly SC tirzepatide 10 mg or 15 mg vs placebo, by baseline sex, age and BMI
- Tirzepatide 10 mgn = 73
- Tirzepatide 15 mgn = 77
- Placebon = 75reference
- Primary endpoint
- Key safety and efficacy outcomes analysed by baseline characteristics
- Follow-up
- Week 72
Methodological detailspost hoc analyses of cardiometabolic parameters
- Post hoc analyses of cardiometabolic parameters
Primary result
As reported in the abstract
Percent body weight change by subgroup, estimated treatment difference vs placebo
- Tirzepatide 10 mg
- estimated treatment difference (females) −17.5%
- Tirzepatide 15 mg
- estimated treatment difference (females) −24.9%
- Tirzepatide 10 mg
- estimated treatment difference (males) −15.1%
- Tirzepatide 15 mg
- estimated treatment difference (males) −18.1%
- Tirzepatide 10 mg
- estimated treatment difference (BMI <35 kg/m²) −18.7%
- Tirzepatide 15 mg
- estimated treatment difference (BMI <35 kg/m²) −21.7%
- Tirzepatide 10 mg
- estimated treatment difference (BMI ≥35 kg/m²) −11.7%
- Tirzepatide 15 mg
- estimated treatment difference (BMI ≥35 kg/m²) −20.4%
Further findings
≥5% weight reduction, across subgroups · week 72
- Tirzepatide (range across subgroups)
- 86%-100%
- Placebo (range across subgroups)
- 18%-30%
Cardiometabolic parameters by subgroup
- All subgroups showed improvements in cardiometabolic parameters with tirzepatide
- Post hoc analyses
Safety
- Safety profiles did not substantially differ by subgroup
Original publication
Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial. Diabetes Obes Metab. Published 25 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →